Literature DB >> 18795397

Etanercept tolerance in a patient with previous infliximab-induced hepatitis.

Heidemarie Becker, Peter Willeke, Wolfram Domschke, Markus Gaubitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18795397     DOI： 10.1007/s10067-008-1000-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  3 in total

1.  Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis.

Authors:  Gary Goldenberg; Joseph L Jorizzo
Journal:  J Dermatolog Treat       Date:  2005       Impact factor: 3.359

2.  A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis.

Authors:  Koji Harada; Yasuhiro Akai; Sachi Koyama; Yasuhide Ikenaka; Yoshihiko Saito
Journal:  Clin Rheumatol       Date:  2008-06-18       Impact factor: 2.980

3.  Serious liver disease induced by infliximab.

Authors:  Gabriel J Tobon; Carlos Cañas; Juan-Jose Jaller; Juan-Carlos Restrepo; Juan-Manuel Anaya
Journal:  Clin Rheumatol       Date:  2006-03-18       Impact factor: 3.650
  3 in total
  8 in total

Review 1.  Autoimmune hepatitis induced by adalimumab with successful switch to abatacept.

Authors:  A Grasland; R Sterpu; S Boussoukaya; I Mahe
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

2.  Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.

Authors:  Ye H Oo; Stefan G Hubscher; David H Adams
Journal:  Hepatol Int       Date:  2010-05-19       Impact factor: 6.047

Review 3.  Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.

Authors:  Roberta Elisa Rossi; Ioanna Parisi; Edward John Despott; Andrew Kenneth Burroughs; James O'Beirne; Dario Conte; Mark Ian Hamilton; Charles Daniel Murray
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 4.  Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Authors:  Marwan Ghabril; Herbert L Bonkovsky; Clarissa Kum; Tim Davern; Paul H Hayashi; David E Kleiner; Jose Serrano; Jim Rochon; Robert J Fontana; Maurizio Bonacini
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

Review 5.  Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review.

Authors:  Maurizio Pompili; Marco Biolato; Luca Miele; Antonio Grieco
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 6.  Infliximab-related hepatitis: discussion of a case and review of the literature.

Authors:  Stefano Mancini; Elisa Amorotti; Sarah Vecchio; Maurizio Ponz de Leon; Luca Roncucci
Journal:  Intern Emerg Med       Date:  2010-01-27       Impact factor: 3.397

Review 7.  Drug-Induced Liver Injury: Pattern Recognition and Future Directions.

Authors:  Tanvir Haque; Eizaburo Sasatomi; Paul H Hayashi
Journal:  Gut Liver       Date:  2016-01       Impact factor: 4.519

Review 8.  Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review.

Authors:  Parth Shah; Vinay Sundaram; Einar Björnsson
Journal:  Hepatol Commun       Date:  2020-01-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.